Tailored Juice-guided Eradication Therapy

NACompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

July 31, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

susceptibility-guided therapy

rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.

DRUG

empirical clarithromycin-based triple therapy

The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University

OTHER

NCT04061447 - Tailored Juice-guided Eradication Therapy | Biotech Hunter | Biotech Hunter